Accompanied by a Rash or Hives: If your itching comes with a rash, hives, or any other skin changes, this could indicate an allergic reaction or a skin condition that needs medical attention
What Has NOT Been Studied No randomized controlled trial has compared microdosing to standard dosing No long-term safety data exists for any alternative dosing protocol Cardiovascular outcomes have not been measured at sub-therapeutic doses The interaction between microdosing and metabolic disease progression is unknown Why People Microdose GLP-1 Drugs Side Effect Reduction Nausea is the most common reason patients seek lower doses
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have been recommended for the treatment of type 2 diabetes for some time, but until now have not been funded in New Zealand
Rare but serious adverse effects including pancreatitis, gallbladder disease, and acute kidney injury (usually secondary to dehydration from vomiting) remain possible
For MCAS and year-round histamine issues, longer-term protocols are more common
